美国至8月14日当周EIA精炼油产量 -5.4万桶/日，前值5万桶/日。

Yushu Technology debuted on Shanghai’s STAR Market today at an issue price of 150.8 yuan, implying a post-issue market value of about 61 billion yuan. Based on 2025 estimates the IPO implies roughly 219x P/E and 36x P/S. Retail subscriptions exceeded 8,000x. Pre-listing offshore private trading priced the stock about 176% above the issue price, with derivatives priced even more aggressively, indicating initial trading is focused on the scarcity value of a leading humanoid-robot name. Refinitiv also noted large-scale replacement by humanoid robots remains constrained by cost and reliability: to achieve a two-year payback total cost would need to fall to roughly 160,000 yuan, while current prices are typically 300,000–500,000 yuan; 50–70% of humanoid robots this year may be deployed for training data collection rather than direct production value.

Merck and Moderna said their experimental personalized mRNA vaccine, given with Merck’s Keytruda, met the primary endpoint in a Phase III trial of more than 1,100 high‑risk or advanced melanoma patients, significantly extending recurrence‑free survival versus Keytruda alone and lowering risk of distant metastasis. The result builds on positive Phase II data earlier this year; the trial will continue to evaluate additional endpoints including overall survival. The companies plan to present data at an upcoming international medical meeting; no timing for a U.S. regulatory submission was disclosed. Merck shares were up about 8% premarket and Moderna shares rose more than 60% premarket.